Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


Acceptability of a Web-Based Health App (PortfolioDiet.app) to Translate a Nutrition Therapy for Cardiovascular Disease in High-Risk Adults: Mixed Methods Randomized Ancillary Pilot Study

Acceptability of a Web-Based Health App (PortfolioDiet.app) to Translate a Nutrition Therapy for Cardiovascular Disease in High-Risk Adults: Mixed Methods Randomized Ancillary Pilot Study

Several recent Canadian population-based studies have shown that many patients at high CVD risk continue to have low-density lipoprotein cholesterol (LDL-C) levels well above the guideline targets [2,3]. LDL-C has been extensively studied and described as a causal factor for CVD [4]. LDL-C levels above the target can result from multiple factors such as insufficient LDL-C lowering with statins, statin-related side effects, suboptimal medication adherence, and treatment inertia [5].

Meaghan E Kavanagh, Laura Chiavaroli, Selina M Quibrantar, Gabrielle Viscardi, Kimberly Ramboanga, Natalie Amlin, Melanie Paquette, Sandhya Sahye-Pudaruth, Darshna Patel, Shannan M Grant, Andrea J Glenn, Sabrina Ayoub-Charette, Andreea Zurbau, Robert G Josse, Vasanti S Malik, Cyril W C Kendall, David J A Jenkins, John L Sievenpiper

JMIR Cardio 2025;9:e58124

A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study

A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study

The Portfolio Diet, or Dietary Portfolio, is a plant-based dietary pattern of cholesterol-lowering foods that has demonstrated drug-like reductions in low-density lipoprotein cholesterol (LDL-C) and other cardiovascular risk factors [1,2]. In a metabolically controlled study, the Portfolio Diet was shown to result in the same LDL-C reduction (approximately 30%) as lovastatin therapy, the first statin to be widely used [1].

Meaghan E Kavanagh, Laura Chiavaroli, Andrea J Glenn, Genevieve Heijmans, Shannan M Grant, Chi-Ming Chow, Robert G Josse, Vasanti S Malik, William Watson, Aisha Lofters, Candice Holmes, Julia Rackal, Kristie Srichaikul, Diana Sherifali, Erna Snelgrove-Clarke, Jacob A Udell, Peter Juni, Gillian L Booth, Michael E Farkouh, Lawrence A Leiter, Cyril W C Kendall, David J A Jenkins, John L Sievenpiper

JMIR Hum Factors 2022;9(2):e34704